as an antioxidant (SN: 8/14/93, p. 109) and an anticarcinogen. Some rodent studies have also demonstrated that certain nascent cancers grow more rapidly when the animals encounter even low levels of light at night (see sidebar).
The first preliminary evidence linking light to cancer in people emerged 8 years ago in a report by Robert A. Hahn of the Centers for Disease Control and Prevention in Atlanta. After combing statistics from a national survey on women who had been hospitalized between 1979 and 1987-including some 11,700 with breast cancer-he computed the incidence of this malignancy in blind and sighted women. If light alters cancer risk through some disruptive effect on melatonin, the epidemiologist reasoned, people whose eyes can't detect light should prove resistant. As a further test, he looked at heart-disease incidence, where melatonin should play no role.
In the May 1991 EPIDEMIOLOGY, Hahn reported that although the profoundly blind women proved as likely as the sighted women to get heart disease, they appeared only half as prone to develop breast cancer.
Probing this idea in more detail, Maria Feychting and her colleagues at the Karolinska Institute in Stockholm have just compared cancer incidence in 1,600 profoundly blind men and women with that in 13,000 people having severe visual impairment. Because members of the second group could still perceive light, Feychting explains, they should resemble sighted people in terms of any light effects on melatonin.
In the September EPIDEMIOLOGY, her team now reports finding that, as predicted, cancer incidence among the visually impaired individuals was virtually identical to that in Sweden's general population. People who were unable to detect light faced only 70 percent of that cancer risk.
Among profoundly blind men, the lower incidence showed up largely in cancers of the prostate, stomach, colon, rectum, skin, and lung. Among profoundly blind women, less cancer occurred in the breast, ovaries, and stomach.
The variety of cancers affected was unexpected. Feychting had anticipated that any change in cancer rates would trace to melatonin's influence on the body's production of estrogen (SN: 7/3/93, p. 10). High lifetime exposure to estrogen can spur the development of certain cancers, notably breast cancer. Instead, she now observes, melatonin may have a more general cancer-suppressing role.
A new Finnish study also compares cancer incidence among profoundly blind people with rates in visually impaired men and women. Slated for publication in the November CANCER CAUSES AND CONTROL, the study found an even more sharply reduced incidence of breast cancer among people unable to perceive light than was seen in the Swedish study. It also found that cancer incidence rates in people with minor visual impairment "were rather close to those in the general population," notes Eero Pukkala, an epidemiologist with the Finnish Cancer Registry in Helsinki and one of the report's authors.
"Throughout the visual categories, we also see a nice trend of decreasing breast cancer risk with decreasing vision," he says. Indeed, this would make sense, argues Stevens, if the eyes of the more visually impaired individuals actually take in or sense less light-as occurs in many eye diseases.
However, in sharp contrast to the Swedish analysis, Pukkala notes, profoundly blind individuals in his study showed no reduction in cancer risk for sites other than the breast. Because the Finnish study analyzed the same types of data as the Swedish study, and in a group of comparable size, he is perplexed by the dissimilarity in their findings for sites other than the breast.
Although the findings of both studies are consistent with the premise that melatonin dis- ruption by light promotes at least breast cancer in humans, Feychting and Pukkala acknowledge that both analyses fall far short of proving it. Their new studies are merely an initial probe of the potential link. Pukkala now plans a larger analysis, pooling data on blind and visually impaired individuals throughout the Nordic countries. He's hoping it will at least home in on the reasons for the discrepancies between the current studies-which he suspects trace to "differences in life habits" between Swedes and Finns such as nutrition, medical care, or social factors.
Such discrepancies also might arise because some blind people may respond to light-even though they did not perceive it-by altering their melatonin-production cycles. Similarly, some sighted people may have abnormal rhythms. Neither Nordic study had the resources to measure each participant's daily cycle of melatonin production-a lengthy and cumbersome procedure that requires frequent, round-the-clock sampling of blood or urine.
Steven W. Lockley, a chronobiologist at the University of Surrey in England, and his colleagues have made such measurements. And in the November 1997 Journal of CLINICAL ENDOCRINOLOGY AND METABOLISM, they noted that melatonin cycles in the blind are anything but predictable.
His group recruited 49 legally blind individuals to participate in a roughly month-long trial. Each collected his or her urine over a 48-hour span each week. The scientists then measured a melatonin byproduct in the urine.
Among the 30 people unable to perceive light, 57 percent had a free-running rhythm-a cycle longer or shorter than 24 hours. "This included every single subject that we've studied who has had their eyes removed," he notes. Another 23 percent had a normally cycling clock, with melatonin reliably peaking at night. The remainder had abnormal or unclassifiable cycles.
Even among the 19 people in the study who could perceive light, 26 percent exhibited abnormal rhythms, with melatonin production peaking at times other than the middle of the night.
"So one can't assume that the melatonin rhythm in all blind people . . . is free-running-or that its peaks in light-sensitive individuals will be normal," observes neuroendocrinologist David E. Blask of the Mary Imogene Bassett Research Institute in Cooperstown, N.Y.
Blask's studies of rats suggest that an abnormal timing of melatonin peaks can have a powerful effect on cancer.
He administered cancer-causing chemicals to rats and then over subsequent weeks injected the animals daily with melatonin. The injections were timed to produce peaks during daylight hours, when melatonin concentrations should have been negligible.
When those injections occurred mid-morning, tumors grew at the same rates seen in animals not receiving injections. However, in animals that received the hormone during the afternoon, "we see an inhibitory effect of the hormone on tumor growth, not only in liver cancers, but also in breast cancers."
The findings suggest "that there is a rhythm of sensitivity within tumor tissues or in cells susceptible to becoming tumors," he told Science News. "And maybe in people who can't perceive light, the oscillating cycle of their biological clock causes their melatonin peaks to coincide with the inhibitory period of tumor cells more often than they do in light-sensitive people."
The growing body of data on melatonin, light, and cancer suggests that certain populations, such as shift workers or others who regularly work in bright light at night, could face unusual risks, Blask argues. Certainly, he says, "the data are suggestive enough to raise eyebrows and prompt further serious study."
William S. Baldwin and J. Carl Barrett of the National Institute of Environmental Health Sciences in Research Triangle Park, N.C., agree that such theories should be tested-by probing the most likely mechanisms of light's effects. "When the melatonin hypothesis was first presented," the pair notes, "no putative melatonin receptors [on cells] were known." Since then, three types have been identified. In the March MOLECULAR CARCINOGENESIS, they lay out the molecular basis for concerns that light at night might prove an endocrine disrupter with the potential to increase cancer risk. They note that recent findings in several laboratories working with cells and with tissues removed from animals indicate that a reduction of melatonin can alter the production of other hormones, may suppress the immune system's ability to recognize and respond to newly emerging cancers, and appears to spur the growth of at least some tumor tissues.
By studying which cells possess melatonin receptors and how cells use them to respond to the hormone-as Barrett's team and others are now doing-science may resolve whether nighttime illumination truly threatens health, and if so, how much and in whom.
Studies now under way are also testing which wavelengths-or colors-are most biologically active. For instance, blue and green light appear especially effective at inhibiting melatonin synthesis in healthy young men, according to studies by Brainard. Indeed, he notes that for some colors, "17 lux was sufficient to produce strong melatonin suppression in these menand some had full suppression with exposure to as little as 5 lux." The latter "is a little more illumination than what you'd have with full moonlight."
Brainard notes that the payoff for finding out what wavelengths are most hormonally disruptive could be insights on how "to tailor nighttime lighting to provide good vision without interfering with the melatonin rhythm." He says that "it may also help us develop more effective lights for use in treating winter depression and sleep disorders."
How much light is too much?
At least in rats, a little light throughout the night can have a dramatic impact on cancer, observes David E. Blask of the Mary Imogene Bassett Research Institute in Cooperstown, N.Y.
Tumors can grow especially rapidly in rodents exposed to constant light, he notes-presumably because of a near-total suppression of their melatonin. To test just how much light was necessary to enhance tumor growth, he implanted liver-cancer cells into rats.
His team housed one group of caged animals in a room illuminated around-the-clock with about 850 lux of white light, which is roughly equivalent to an office with medium lighting. A second group of animals spent their days in 850 lux but their nights in total darkness. A third group encountered almost the same light-dark cycle. The only difference: 0.2 lux leaked in at the bottom of the door to their room from a hallway outside-illumination well below that typical of a moonless night, he says.
In the October 1997 LABORATORY ANIMAL SCIENCE, Blask's team reported that tumors in animals exposed to the crack of light coming under the room's door grew almost twice as fast as those in animals getting a night of total darkness. Indeed, he says, "animals exposed to the low-level light contamination had a tumor-growth rate virtually identical to that in the animals exposed to bright, constant light." He has just replicated the findings in an experiment in which the lighting was more rigorously controlled. s s 
